JSPRJasper Therapeutics, Inc.

Nasdaq www.jaspertherapeutics.com


$ 19.37 $ 0.67 (3.6 %)    

Monday, 09-Sep-2024 15:59:25 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 19.3
$ 19.17
$ 19.23 x 100
-- x --
$ 19.13 - $ 19.60
$ 4.00 - $ 31.01
95,807
na
291.53M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-18-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-24-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-jasper-therapeutics

Cantor Fitzgerald analyst Josh Schimmer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight.

 jmp-securities-initiates-coverage-on-jasper-therapeutics-with-market-outperform-rating-announces-price-target-of-70

JMP Securities analyst Silvan Tuerkcan initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform rati...

 evercore-isi-group-maintains-outperform-on-jasper-therapeutics-maintains-65-price-target

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $...

 rbc-capital-maintains-outperform-on-jasper-therapeutics-lowers-price-target-to-68

RBC Capital analyst Gregory Renza maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target ...

 hc-wainwright--co-reiterates-buy-on-jasper-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...

 jasper-therapeutics-q2-2024-gaap-eps-097-beats-108-estimate-cash-1068m

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-buy-on-jasper-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...

 btig-initiates-coverage-on-jasper-therapeutics-with-buy-rating-announces-price-target-of-90

BTIG analyst Justin Zelin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Targ...

 stifel-initiates-coverage-on-jasper-therapeutics-with-buy-rating-announces-price-target-of-86

Stifel analyst Ben Burnett initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Tar...

 cantor-fitzgerald-reiterates-overweight-on-jasper-therapeutics

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight.

 hc-wainwright--co-reiterates-buy-on-jasper-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...

 hc-wainwright--co-reiterates-buy-on-jasper-therapeutics-maintains-65-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...

 jasper-therapeutics-q1-eps-103-beats-123-estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-initiates-coverage-on-jasper-therapeutics-with-buy-rating-announces-price-target-of-65

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and a...

 evercore-isi-group-initiates-coverage-on-jasper-therapeutics-with-outperform-rating-announces-price-target-of-65

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rat...

 rbc-capital-initiates-coverage-on-jasper-therapeutics-with-outperform-rating-announces-price-target-of-70

RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Outperform rating and annou...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION